Product details

Share this page:
Published by:
Darden Business Publishing (2010)
25 January 2010
18 pages
Data source:
Published sources


This is the first of a two-case series '' UVA-BC-0204 to UVA-BC-0205''. To protect patient confidentiality, Abiomed, makers of the AbioCor artificial heart, adopt a 30-day ''quiet period'' surrounding implantations, which is construed by mainstream media as a ''news blackout.'' In late 2002, James Quinn, the fifth transplant recipient, dies after 289 days. A month later, in a New York Times article describing Quinn''s pain and suffering, Quinn''s widow claims that her husband had not been adequately informed of the likely ordeal. This case raises issues about transparency and communication with stakeholders. The A-case may lead some students to focus on the public sensationalism surrounding the Quinn story, but a closer examination of the case reveals that the more urgent issue for AbioMed is getting the stalled clinical trial back on track and bouying a slumping stock price. The B-case provides a detailed epilogue, including reactions to the Quinns'' informed consent lawsuit and AbioMed''s handling of the on-going clinical trial and investor relations.


Ethics; Communication policy; Transparency; Information; Informed consent; Clinical trial; Crisis; Investor relations; Public relations; Media relations

Access this item
View our pricing guide
or to see prices.

Reviews & usage